Elranatamab (Elrexfio®). HTA ID: 23066

Assessment Status Full HTA submission received from Applicant
HTA ID 23066
Drug Elranatamab
Brand Elrexfio®
Indication Elranatamab (Elrexfio®) is indicated as monotherapy for the treatment of adult patients with relapsed, refractory multiple myeloma, who have received at least three prior therapies (including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody) and have demonstrated disease progression on the last therapy.
Assessment Process
Rapid review commissioned 13/10/2023
Rapid review completed 29/11/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of elranatamab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.
Full pharmacoeconomic assessment commissioned by HSE 31/01/2024
Pre-submission consultation with Applicant 20/03/2024
Full submission received from Applicant 13/05/2024